Tregalizumab

Names

[ CAS No. ]:
1207446-68-1

[ Name ]:
Tregalizumab

Biological Activity

[Description]:

Tregalizumab is a humanized anti-human CD4 monoclonal antibody (IgG1 type) that selectively activates the suppressive properties of regulatory T cells (Tregs) in vitro. Tregalizumab can be used in the research of autoimmune diseases (resulting from insufficient Treg activity) and allergies[1][2][3].

[Related Catalog]:

Signaling Pathways >> Others >> Others

Research Areas >> Inflammation/Immunology

[Target]

CD4[1][2][3].

[In Vitro]

Tregalizumab 能够激活调节性 T 细胞的抑制能力[1]。 Tregalizumab 减少用破伤风类毒素刺激 (以剂量依赖性方式) 分离的 PBMC 的增殖和细胞因子分泌[1]。 Tregalizumab (0-30 µg/mL; 18 h) 处理 PBMC 诱导 T 细胞的 CD4 下调[2]。 Tregalizumab 主要诱导炎症部位的 CD4 下调[2]。 Cell Viability Assay[2] Cell Line: PBMC cells Concentration: 0-30 µg/mL Incubation Time: 18 h Result: Induced CD4 down-modulation of T cells.

[References]

[1]. König M, et al. Tregalizumab - A Monoclonal Antibody to Target Regulatory T Cells. Front Immunol. 2016 Jan 25;7:11.

[2]. Vogel S, et al. Antibody induced CD4 down-modulation of T cells is site-specifically mediated by CD64(+) cells. Sci Rep. 2015 Dec 16;5:18308.

[3]. Helling B, et al. A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway. Immunol Cell Biol. 2015 Apr;93(4):396-405.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.